SINGAPUR (dpa-AFX) - Biotechnology company Novavax, Inc. (NVAX) announced Wednesday its submission to the Singapore Health Sciences Authority (HSA) for interim authorization of its COVID-19 vaccine
GAITHERSBURG, Md., Nov. 24, 2021 /PRNewswire/ Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its submission to the Singapore Health Sciences Authority (HSA) for interim authorization of its COVID-19 vaccine under the Pandemic Special Access Route (PSAR). "Today's filing reinforces our ongoing commitment to delivering.
MOH in advanced talks with AstraZeneca on potential buy of its Covid-19 treatment drug straitstimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from straitstimes.com Daily Mail and Mail on Sunday newspapers.